Skip To The Main Content

Risk Management Shines Light on ICH Q12 Use for Biologics

World Management

Wanting pharma companies to consider quality-by-design (QbD) elements throughout a product’s entire lifecycle, including post-approval changes, through integration of risk- and knowledge-based approaches, seems to have become a global regulatory expectation. For biologics, however, using these approaches is more complex and companies cannot simply adopt the same strategies used for traditional small molecules.

You need to Login to view the full article. Please Login. Not a Member? Join today!
SHARE THIS ARTICLE
Advertisement

PDA Members Save Substantially